Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains delta-9-tetrahydrocannabinol (THC)...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.

Psychological medicine·2024
Same author

An early economic analysis of medical cannabis for the treatment of chronic pain.

Expert review of pharmacoeconomics & outcomes research·2024
Same author

Authors' response to letter 'On the use of open-label studies for the evaluation of cannabis-based products for the treatment of long-COVID'.

British journal of clinical pharmacology·2024
Same author

Using real world evidence to optimize care: the case of medical cannabis.

Expert review of pharmacoeconomics & outcomes research·2024
Same author

Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial.

British journal of clinical pharmacology·2023
Same author

Adverse childhood experiences and adolescent cannabis use trajectories: findings from a longitudinal UK birth cohort.

The Lancet. Public health·2023
Same journal

Neuroimaging in older-age bipolar disorder.

Current opinion in psychiatry·2026
Same journal

Repetitive transcranial magnetic stimulation treatment for obsessive-compulsive disorder.

Current opinion in psychiatry·2026
Same journal

Pharmacological maintenance treatment in older age bipolar disorder.

Current opinion in psychiatry·2026
Same journal

Harmful behaviours and suicide in later life bipolar disorder.

Current opinion in psychiatry·2026
Same journal

Urbanization, wildfire exposure, and youth mental health: a narrative review.

Current opinion in psychiatry·2026
Same journal

Bipolar disorder and the risk of developing dementia - a systematic review and meta-analysis.

Current opinion in psychiatry·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

The challenges in developing a rational cannabis policy.

Wayne Hall1, Michael Lynskey

  • 1School of Population Health, University of Queensland, Herston, Queensland, Australia. w.hall@sph.uq.edu.au

Current Opinion in Psychiatry
|March 19, 2009
PubMed
Summary
This summary is machine-generated.

A rational cannabis policy requires evaluating harms from cannabis use and prohibition. Evidence shows cannabis use risks, while prohibition has economic costs and fails to deter use, suggesting policy reform is needed.

More Related Videos

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

Related Experiment Videos

Last Updated: Jun 24, 2026

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

Area of Science:

  • Public Health
  • Epidemiology
  • Social Science

Background:

  • Cannabis policy aims to minimize harms from both use and control measures.
  • Reviewing epidemiological and social research is crucial for informed policy.
  • Understanding the costs and benefits of cannabis prohibition is essential.

Purpose of the Study:

  • To review epidemiological evidence on cannabis use harms.
  • To examine social research on the costs and benefits of cannabis prohibition.
  • To inform the development of a more rational cannabis policy.

Main Methods:

  • Review of recent epidemiological studies on cannabis use.
  • Analysis of social research concerning cannabis prohibition.
  • Synthesis of evidence on health consequences and policy impacts.

Main Results:

  • Cannabis use is linked to increased risk of road crash injury, dependence, respiratory issues, and psychosis in young adults.
  • Chronic cannabis use may negatively impact educational outcomes and potentially increase use of other illicit drugs.
  • Cannabis prohibition incurs significant economic costs, fosters a black market, and has not deterred use, while foregone tax revenue is substantial.

Conclusions:

  • Developing rational cannabis policy necessitates evaluating health consequences of use and policy costs/benefits.
  • Liberalizing international controls may allow for policy experimentation by member states.
  • Evidence supports re-evaluation of current cannabis control strategies and potential policy reforms.